Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma Pharmaceutical TechnologyThe FDA has issued a complete response letter to Replimune's biologics license application concerning the RP1 therapy.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA hands another rejection to Replimune’s melanoma therapyNext: Data backs GSK’s ovarian cancer blockbuster hopes Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
